NDAOPHTHALMICOINTMENT
Approved
Mar 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
CILOXAN (ciprofloxacin hydrochloride) by Novartis is clinical pharmacology: systemic absorption: absorption studies in humans with the ciprofloxacin ointment have not been conducted, however, based on studies with ciprofloxacin solution, 0. Approved for mycobacterium avium-intracellulare infection, hiv infections. First approved in 1998.
Drug data last refreshed 22h ago
Mechanism of Action
CLINICAL PHARMACOLOGY: Systemic Absorption: Absorption studies in humans with the ciprofloxacin ointment have not been conducted, however, based on studies with ciprofloxacin solution, 0.3%, mean maximal concentrations are expected to be less than 2.5 ng/mL. Microbiology: Ciprofloxacin has in vitro…
Worked on CILOXAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.